Results 11 to 20 of about 51,995 (213)

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network. [PDF]

Clin Pharmacol Ther
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Jayachandran P, Ladumor MK, Vlasakakis G, Riselli A, Ilic KV, van Wijk RC, Elmeliegy M, Mukker JK, Sawant-Basak A, Long T, Dong J, Rayad N, Zhang T, DRO Network.   +13 more
europepmc   +2 more sources

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis

Frontiers in Pharmacology, 2022
Objective: After Gemstone-302 was published in Lancet in January 2022, seven PD-(L)1 inhibitors launched or about to be launched in China, but there are no head-to-head RCTs reporting the comparative efficacy for squamous non-small cell lung cancer (sq ...
Mingye Zhao, Mingye Zhao, Taihang Shao, Taihang Shao, Yinan Ren, Yinan Ren, Caicun Zhou, Wenxi Tang, Wenxi Tang   +8 more
doaj   +1 more source

Knowledge, Attitude, and Practices of Moroccan Retail Pharmacists towards Veterinary Medicines

Advances in Pharmacological and Pharmaceutical Sciences, 2022
This is the first study conducted in Morocco to assess knowledge, attitude, and practices of retail pharmacists regarding veterinary medicines. It is a cross-sectional study.
Zeinab Snoussi, Samir Ahid
doaj   +1 more source

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven, Gallagher, Meghan, Mitchell, Paul, Thomas, Simu, White, Richard   +4 more
core   +1 more source

A survey of pharmacists' knowledge, attitudes and barriers in pharmaceutical care concept in Poland

BMC Medical Education, 2021
Background The major goals of pharmaceutical care (PC) are to improve the patient’s quality of life and ensure safety of pharmacotherapy. Inclusion of a pharmacist in the multidisciplinary team caring for the patient and integration of state-of-the-art ...
Dorota Kopciuch, Anna Paczkowska, Tomasz Zaprutko, Piotr Ratajczak, Elżbieta Nowakowska, Krzysztof Kus   +5 more
doaj   +1 more source

Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method

Cost Effectiveness and Resource Allocation, 2023
Objectives Monetizing health has sparked controversy and has implications for pricing strategies of emerging health technologies. Medical insurance payers typically set up thresholds for quality-adjusted life years (QALY) gains based on health ...
Qian Peng, Yue Yin, Min Liang, Mingye Zhao, Taihang Shao, Yaqian Tang, Zhiqing Mei, Hao Li, Wenxi Tang   +8 more
doaj   +1 more source

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis

Frontiers in Pharmacology, 2023
Background and objective: Non-small cell lung cancer (NSCLC) is one of the most malignant cancer types that causes substantial economic burden in China.
Xi Chen, Xi Chen, Mingye Zhao, Mingye Zhao, Lei Tian, Lei Tian   +5 more
doaj   +1 more source

Strengthening international patient advocacy perspectives on patient involvement in HTA within the HTAi Patient and Citizen Involvement Interest Group – Commentary [PDF]

, 2017
PLAIN LANGUAGE SUMMARYHealth Technology Assessment (HTA) is an evidence-based decision-making process, focusing on evaluating health technologies for funding within a healthcare system.
Anna Mae Scott, Janet L. Wale, Neil Bertelsen, Nick Meade, null null   +4 more
core   +2 more sources

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Arthritis Research & Therapy, 2017
Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim   +4 more
doaj   +1 more source

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model

Frontiers in Public Health, 2023
BackgroundA total of 11 treatment sequences for advanced wild-type squamous non-small cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines, consisting of seven first-line and three second-line treatments.
Mingye Zhao, Mingye Zhao, Taihang Shao, Taihang Shao, Zhuoyuan Chi, Zhuoyuan Chi, Wenxi Tang, Wenxi Tang   +7 more
doaj   +1 more source